Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways

Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Helus Pharma ( (HELP) ) has issued an update. Helus Pharma on April 20, 2026 expressed support for a new White House Executive Order designed to accelerate research, regulatory pathways and patient access for psychedelic treatments targeting serious mental health conditions. The company framed the move as a policy milestone that underscores the importance of rigorous, evidence-based development and scalable delivery of safe therapies. The Executive Order outlines measures such as potential priority FDA review for psychedelic therapies with Breakthrough Therapy designation, expanded access for eligible patients, greater federal funding for state programs and closer coordination among health agencies, including HHS, FDA and the Department of Veterans Affairs. It also calls for timely rescheduling of therapies that clear late-stage trials and win regulatory approval, a step that could smooth commercialization and reimbursement. Helus highlighted that its lead program, HLP003, a novel serotonergic agonist in Phase 3 for adjunctive treatment of major depressive disorder and already granted FDA Breakthrough Therapy status, is well positioned to benefit from a more supportive U.S. policy environment. The company noted that millions of patients with major depressive disorder and generalized anxiety disorder continue to respond inadequately to current treatments, arguing that the Executive Order could hasten the development and availability of innovative options. Management said Helus will continue advancing its clinical pipeline and collaborating with regulators, clinicians and research partners as psychedelic-based and NSA therapies move closer to potential mainstream adoption. For investors and other stakeholders, the shift in U.S. federal posture may reduce regulatory friction and strengthen the industry’s long-term outlook, even as outcomes remain contingent on successful late-stage trials and eventual approvals. The most recent analyst rating on (HELP) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Helus Pharma stock, see the HELP Stock Forecast page. More about Helus Pharma Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s lead NSA, HLP003, is in Phase 3 for adjunctive treatment of major depressive disorder with FDA Breakthrough Therapy designation, while HLP004 is in Phase 2 for generalized anxiety disorder, supported by a broader research portfolio across North America and Europe. Helus aims to address large unmet needs in depression, anxiety and other serious mental health conditions where existing therapies are often insufficient, positioning itself within the emerging psychedelic-inspired treatments segment. Operating in Canada, the United States, the United Kingdom and Ireland, it seeks to introduce NSAs that can deliver durable improvements in mental health outcomes and strengthen its standing in the fast-evolving neuropsychiatric drug development market. Average Trading Volume: 797,682 Technical Sentiment Signal: Sell Current Market Cap: $1.4M